Thyroid Cancer (Medullary Carcinoma)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    RET Mutation 43 Vandetanib (RET inhibitor) (FDA approved):
    • Phase 3: PR 46%; PFS 31 mo (estimated), OS > 27 mo (median) (7)*
    Cabozantinib (RET inhibitor) (FDA approved):
    • Phase 3: PR 28%; PFS 11 mo, OS 21 mo (8)
    Sunitinib (VEGFR/PDGFR/RET/KIT/FLT3 inhibitor):
    • Phase 2: PR 35% (9)
    Sorafenib (VEGFR/RET inhibitor) (FDA approved):
    • Phase 2: PR 22%, SD 72% (10)
    Lenvatinib (E7080) (VEGFR inhibitor):
    • Phase 2: PR 49%, SD > 6 mo 27% (11)
    RAS Mutation
    Other topics in Targets by Organ Site